Open Access

Exogenous lipids promote the growth of breast cancer cells via CD36

  • Authors:
    • Jing Zhao
    • Zheng Zhi
    • Chao Wang
    • Hanying Xing
    • Guangyao Song
    • Xian Yu
    • Yajun Zhu
    • Xing Wang
    • Xuemei Zhang
    • Yan Di
  • View Affiliations

  • Published online on: August 1, 2017     https://doi.org/10.3892/or.2017.5864
  • Pages: 2105-2115
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer cells present sustained de novo fatty acid (FA) synthesis with increased production of saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs). This change in FA metabolism is associated with overexpression of stearoyl-CoA desaturase 1 (SCD1), which catalyses the transformation of SFAs into MUFAs (e.g., oleic acid). In this study, we provide new evidence that SCD1 inhibition leads to the anti-proliferation effect of breast cancer cells through induction of apoptosis, cell cycle arrest and migration prevention. However, the antitumor effect of the SCD1 inhibitor can be reversed by exogenous oleic acid. We hypothesize that, in addition to de novo synthesis, cancer cells may uptake exogenous FAs actively. CD36, also known as FA translocase (FAT), that functions as a transmembrane protein and mediates the uptake of FAs, is observed to be highly expressed in breast cancer tissues. Furthermore, the anti-proliferation effect caused by the SCD1 inhibitor can not be reversed by exogenous oleic acid supplementation in CD36 knockdown breast cancer cells. Our study revealed that the lipid metabolism of breast cancer is regulated not only by de novo lipogenesis but also by the availability of lipids outside cancer cells. Consistent with FA synthesis, FA uptake and transport will be another important target pathway for anticancer therapy, and the FA channel protein CD36 may provide a promising therapeutic target. Lipogenesis combined with FA transport will be a new orientation for antitumor therapy.
View Figures
View References

Related Articles

Journal Cover

October-2017
Volume 38 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, Zhu Y, Wang X, Zhang X, Di Y, Di Y, et al: Exogenous lipids promote the growth of breast cancer cells via CD36. Oncol Rep 38: 2105-2115, 2017.
APA
Zhao, J., Zhi, Z., Wang, C., Xing, H., Song, G., Yu, X. ... Di, Y. (2017). Exogenous lipids promote the growth of breast cancer cells via CD36. Oncology Reports, 38, 2105-2115. https://doi.org/10.3892/or.2017.5864
MLA
Zhao, J., Zhi, Z., Wang, C., Xing, H., Song, G., Yu, X., Zhu, Y., Wang, X., Zhang, X., Di, Y."Exogenous lipids promote the growth of breast cancer cells via CD36". Oncology Reports 38.4 (2017): 2105-2115.
Chicago
Zhao, J., Zhi, Z., Wang, C., Xing, H., Song, G., Yu, X., Zhu, Y., Wang, X., Zhang, X., Di, Y."Exogenous lipids promote the growth of breast cancer cells via CD36". Oncology Reports 38, no. 4 (2017): 2105-2115. https://doi.org/10.3892/or.2017.5864